Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Males and females subjects aged ≥65 years at day of vaccination who are willing and able to comply to study procedures.~Exclusion Criteria:~1. Individuals with behavioral or cognitive impairment or a psychiatric condition or with a history of any illness that,in the opinion of the investigator, would have interfered with the subject's ability to participate in the study.~2. Individuals who were not able to comprehend and/or follow all required study procedures for the whole period of the study.~3. Known or suspected impairment/alteration of immune function.~4. Individuals with a known bleeding diathesis.~5. History of Guillain-Barré syndrome.~6. Individuals with history of allergy to vaccine components and/or a history of any anaphylaxis, serious vaccine reactions or hypersensitivity to influenza viral proteins, egg proteins (including ovalbumin), polymyxin, neomycin, betapropiolactone, thimerosal/ sodium ethylmercurothiosalicylate/ mercury and nonylphenolethoxylate/ nonoxynol-9 (spermicide).~7. Receipt of another investigational agent within 30 days prior to enrollment in the study or before completion of the safety follow-up period in another study.~8. Individuals who had received any other vaccines within 2 weeks for inactivated vaccines or 4 weeks for live vaccines prior to enrollment in this study or who had planned to receive any vaccine within 3 weeks from the study vaccine.~9. Individuals who had received vaccination against seasonal influenza in the previous 6 months.~10. Individuals with oral temperature ≥38.0°C (≥100.4°F) on day of study vaccination.~11. Individuals with history of substance or alcohol abuse within the past 2 years.~12. Individuals providing consent who did not consent to the retention of their serum samples after study completion.~13. Elective surgery or hospitalization planned to occur during the treatment phase or during the follow-up phase that, according to the opinion of the investigator, might have poses additional risk to the subject.~14. Subjects from whom blood could not be drawn at visit 1.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- aTIV (Type: EXPERIMENTAL): Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).
- Licensed TIV (Type: EXPERIMENTAL): Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).

Based on this trial design, predict the completion outcome and termination type (if applicable).